Nabi Sees Positive Interim Results of Anti-Nicotine Study

Nabi Biopharmaceuticals received promising interim results from its Phase II NicVAX immunogenicity study.

The study assessed the antibody response and safety of a 400-microgram, six-dose immunization schedule with the drug. Results showed that 80 percent of subjects achieved the target antibody level at 14 weeks, Nabi said.

The drug stimulates the immune system to produce antibodies that bind to nicotine, which then block nicotine from reaching receptors in the brain. This prevents the addictive sensations experienced by users of nicotine products.